Position in SPRY
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$4,642,596
+$15,710 QoQ
Shares Held
579,600
+0.6% QoQ
Ownership
0.583%
of shares outstanding
% of Portfolio
2.71%
of 13F equity value
Holder Rank
#22
of 205 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SPRY Over Time
Shares Held
Position Value (USD)
Derivatives in SPRY
reported options exposure · as of Dec 31, 2025CallValue
$17,475
CallShares
1,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pavaki Capital Management LLC holds $44,033,947 across 21 Biotechnology names. SPRY ranks #4 (10.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIST |
Milestone Pharmaceuticals Inc.
|
9,067,848 | $12,150,916 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,900 | $6,173,046 | |
| 3 | ARQT |
Arcutis Biotherapeutics, Inc.
|
187,000 | $4,903,140 | |
| 4 | SPRY |
ARS Pharmaceuticals, Inc.
This page
|
579,600 | $4,642,596 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
11,100 | $3,508,599 | |
| 6 | HRMY |
Harmony Biosciences Holdings, Inc.
|
73,000 | $2,657,930 | |
| 7 | RPRX |
Royalty Pharma plc
|
44,000 | $2,467,080 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
66,600 | $2,257,074 |
All Filings in SPRY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,642,596 | 579,600 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $4,626,886 | 576,200 | Shares | Sole | 2026-08-07 | |
| 2025-12-31 | $17,475 | 1,500 | Call | Sole | 2026-08-07 | |
| 2025-12-31 | $13,653,800 | 1,172,000 | Shares | Sole | 2026-08-07 | |
| No filing history on record for this holder in this stock. | ||||||